JP2024508545A5 - - Google Patents
Info
- Publication number
- JP2024508545A5 JP2024508545A5 JP2023553660A JP2023553660A JP2024508545A5 JP 2024508545 A5 JP2024508545 A5 JP 2024508545A5 JP 2023553660 A JP2023553660 A JP 2023553660A JP 2023553660 A JP2023553660 A JP 2023553660A JP 2024508545 A5 JP2024508545 A5 JP 2024508545A5
- Authority
- JP
- Japan
- Prior art keywords
- deuterium
- disorders
- hydrogen
- alkyl
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163155634P | 2021-03-02 | 2021-03-02 | |
| US63/155,634 | 2021-03-02 | ||
| PCT/CA2022/050295 WO2022183287A1 (en) | 2021-03-02 | 2022-03-02 | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024508545A JP2024508545A (ja) | 2024-02-27 |
| JP2024508545A5 true JP2024508545A5 (enExample) | 2025-03-04 |
Family
ID=83153685
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553660A Pending JP2024508545A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
| JP2023553664A Pending JP2024508922A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023553664A Pending JP2024508922A (ja) | 2021-03-02 | 2022-03-02 | セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20240166630A1 (enExample) |
| EP (2) | EP4301730A4 (enExample) |
| JP (2) | JP2024508545A (enExample) |
| KR (2) | KR20230154220A (enExample) |
| CN (2) | CN117500788A (enExample) |
| AU (2) | AU2022229037A1 (enExample) |
| BR (1) | BR112023017754A2 (enExample) |
| CA (2) | CA3210275A1 (enExample) |
| IL (2) | IL305481A (enExample) |
| MX (2) | MX2023010316A (enExample) |
| WO (2) | WO2022183288A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| KR20250053871A (ko) * | 2022-08-31 | 2025-04-22 | 사이빈 아이알엘 리미티드 | 트립타민 화합물, 조성물, 및 사용 방법 |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| CN121752545A (zh) * | 2023-11-06 | 2026-03-27 | 宜昌人福药业有限责任公司 | 一种n,n-二甲基色胺衍生物及其药物组合物、制备方法和用途 |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2025104490A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL170330B1 (pl) * | 1990-10-15 | 1996-11-29 | Pfizer | Sposób wytwarzania nowych pochodnych indolu PL PL PL PL PL PL |
| US5578612A (en) * | 1990-10-15 | 1996-11-26 | Pfizer Inc. | Indole derivatives |
| DK1859798T3 (en) * | 2001-03-29 | 2016-03-21 | Lilly Co Eli | N- (2-arylethyl) -BENZYLAMINER as antagonists of 5-HT6 receptor |
| TWI318621B (en) * | 2006-08-03 | 2009-12-21 | Nat Bureau Of Controlled Drugs Dept Of Health | A series of deuterium labelled compounds as drug testing standards and their preparations |
| US20090062367A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched eletriptan |
| CN108484449A (zh) * | 2011-09-09 | 2018-09-04 | 蓝瑟斯医学影像公司 | 用于合成和使用显像剂的组合物、方法和系统 |
| WO2018094106A2 (en) * | 2016-11-16 | 2018-05-24 | University Of South Florida | ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES |
| CA3132731A1 (en) * | 2019-03-07 | 2020-09-10 | University Of Padova | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) * | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| KR20220137081A (ko) * | 2020-02-04 | 2022-10-11 | 마인드셋 파마 인크. | Cns 장애의 치료를 위한 세로토닌성 사이키델릭 작용제로서의 실로신 유도체 |
| BR112022015379A2 (pt) * | 2020-02-04 | 2022-09-27 | Mindset Pharma Inc | Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc |
| WO2021218896A1 (zh) * | 2020-04-26 | 2021-11-04 | 江苏恒瑞医药股份有限公司 | 海鞘素类衍生物及其制备方法与医药用途 |
| WO2021234608A1 (en) * | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US12240813B2 (en) * | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
-
2022
- 2022-03-02 AU AU2022229037A patent/AU2022229037A1/en active Pending
- 2022-03-02 KR KR1020237033368A patent/KR20230154220A/ko active Pending
- 2022-03-02 JP JP2023553660A patent/JP2024508545A/ja active Pending
- 2022-03-02 MX MX2023010316A patent/MX2023010316A/es unknown
- 2022-03-02 EP EP22762289.1A patent/EP4301730A4/en active Pending
- 2022-03-02 CN CN202280032370.6A patent/CN117500788A/zh active Pending
- 2022-03-02 WO PCT/CA2022/050296 patent/WO2022183288A1/en not_active Ceased
- 2022-03-02 BR BR112023017754A patent/BR112023017754A2/pt unknown
- 2022-03-02 MX MX2023010317A patent/MX2023010317A/es unknown
- 2022-03-02 EP EP22762290.9A patent/EP4301747A4/en active Pending
- 2022-03-02 AU AU2022229695A patent/AU2022229695A1/en active Pending
- 2022-03-02 CA CA3210275A patent/CA3210275A1/en active Pending
- 2022-03-02 WO PCT/CA2022/050295 patent/WO2022183287A1/en not_active Ceased
- 2022-03-02 IL IL305481A patent/IL305481A/en unknown
- 2022-03-02 CN CN202280032373.XA patent/CN117242065A/zh active Pending
- 2022-03-02 CA CA3210270A patent/CA3210270A1/en active Pending
- 2022-03-02 JP JP2023553664A patent/JP2024508922A/ja active Pending
- 2022-03-02 US US18/279,293 patent/US20240166630A1/en active Pending
- 2022-03-02 KR KR1020237033351A patent/KR20230154219A/ko active Pending
- 2022-03-02 US US18/279,290 patent/US20240166599A1/en active Pending
- 2022-03-02 IL IL305622A patent/IL305622A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024508545A5 (enExample) | ||
| JP2023513679A5 (enExample) | ||
| JP2024508922A5 (enExample) | ||
| JP2023512821A5 (enExample) | ||
| RU2119484C1 (ru) | Тропонзамещенный фенилоксазолидинон или его фармацевтически приемлемые соли или гидраты | |
| IL295371A (en) | Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders | |
| US5574055A (en) | Oxazolidinone derivatives | |
| JP2023553094A5 (enExample) | ||
| JP6321825B2 (ja) | 神経形成を刺激することができるｎ−フェニル−ラクタム誘導体及び神経障害の処置におけるそれらの使用 | |
| JP2017031198A (ja) | 多環式化合物及びその使用方法 | |
| UY24375A1 (es) | Procedimiento para la preparacion de derivados de quinolin-4 -carboxamida | |
| AR068049A1 (es) | El uso de derivados de benzamida para el tratamiento de trastornos del snc y los mencionados derivados de benzamida. | |
| JP2018065830A (ja) | ヘテロアリール化合物およびそれらの使用方法 | |
| CA2428039A1 (en) | Serotonergic agents | |
| JP2025513462A5 (enExample) | ||
| JP2024543973A5 (enExample) | ||
| RU2013124827A (ru) | Производные индола и способ их получения | |
| JP2025513461A5 (enExample) | ||
| JP2025502614A5 (enExample) | ||
| JP3856829B2 (ja) | オキサゾリジノン誘導体、その製造及び治療的使用 | |
| CA2464997A1 (en) | Silicon compounds | |
| AR059182A1 (es) | Utilizacion de 2-imidazoles para el tratamiento de trastornos del snc,proceso para obtener los compuestos | |
| JP2008508251A5 (enExample) | ||
| JP5947907B2 (ja) | Ｋｃｎｑカリウムチャネル作動薬として使用できる新規な化合物、その製造方法および用途 | |
| US6696450B2 (en) | Serotonergic agents with long-acting in vivo effects |